Drug Target Review

APRIL 7, 2025

This stability enables the application of hit identification approaches such as fragment-based screening (FBS). The development of PoLiPa technology marks a new era in membrane protein drug discovery, rendering otherwise difficult targets accessible to structural biology, biophysical assays and other screening technologies.

Fragment Screening 52

Fragment Screening Drugs Small Molecule Biophysical Assays 52

Drug Target Review

NOVEMBER 1, 2023

In terms of compound libraries, we have a high-throughput screening library of about 200,000 ligands. For fragment screening, which are much smaller compounds, we have a library of about 3000 fragments. We can screen with many different formats and modalities.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Sygnature Discovery

JUNE 17, 2024

Comprehensive Assay Development for Diverse Applications Our team here at Sygnature Discovery, comprised of expert biophysicists, is highly experienced in a variety of target classes and drug modalities. Sygnature Discovery’s Biophysical Assay Development Capabilities: 1.

Biophysical Assays 52

Biophysical Assays Screening Hits Assay Development Fragment Screening 52